Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G56W1 weekly vs Teribone in postmenopausal osteoporosis
ChiCTR1900026859Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of teriparatide in postmenopausal osteoporosis (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Change in lumbar spine bone mineral density, Pharmacokinetics of G56W1 and 1 more. Started Mar 2019; status: recruiting.
02
Drugs
teriparatide
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on ChiCTR1900026859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026859.